drugset / Trial / NCT07865130
Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will determine the safety and tolerability of RVU120 as a single agent and in combination with the mTOR inhibitor everolimus in children with recurrent or progressive G3 or G4 medulloblastoma and provide preliminary data regarding the efficacy of this treatment approach.
Timeline
- Start
- 2026-09
- Primary completion
- 2033-06
- Completion
- 2033-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | — |
| Subject | SEL-120 FREE BASE | Small molecule | — | — |